Abstract: The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.
Type:
Grant
Filed:
October 15, 2018
Date of Patent:
June 30, 2020
Assignee:
Nektar Therapeutics
Inventors:
Michael D. Bentley, Sean M. Culbertson, Samuel P. McManus
Abstract: The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.
Type:
Grant
Filed:
October 24, 2017
Date of Patent:
June 16, 2020
Assignee:
Nektar Therapeutics
Inventors:
Sean M. Culbertson, Antoni Kozlowski, Tony Drew Vinson
Abstract: The invention relates to (among other things) a method comprising the steps of (a) administering to a patient a PARP-inhibiting amount of a PARP inhibitor; and (b) administering to the patient a topoisomerase I-inhibiting amount of a long-acting topoisomerase I inhibitor.
Type:
Grant
Filed:
January 13, 2015
Date of Patent:
May 19, 2020
Assignee:
Nektar Therapeutics
Inventors:
Ute Hoch, Nancy Marie Burns, Deborah H. Charych
Abstract: Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
May 12, 2020
Assignee:
Nektar Therapeutics
Inventors:
J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
Abstract: Apparatus (500) and components for coupling fluid or gas conducting elements, such as apparatus and components for connecting a nebulizer (501) with a gas flow system. In particular, the apparatus (500) and components are useful for connecting, in a gas-tight and quick release manner, a nebulizer (501) to a pressure-assisted breathing system, such as a mechanical ventilator or a continuous airway pressure (“CPAP”) system.
Type:
Application
Filed:
June 11, 2019
Publication date:
April 30, 2020
Applicant:
Nektar Therapeutics
Inventors:
James B. FINK, Gavan O'SULLIVAN, Paul DUNNE, Declan MORAN, John POWER, Niall SMITH
Abstract: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.
Type:
Grant
Filed:
October 3, 2017
Date of Patent:
January 7, 2020
Assignee:
Nektar Therapeutics
Inventors:
Michael A. Eldon, Shibani S. Harite, Tamra L. Barker
Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
Type:
Grant
Filed:
March 2, 2018
Date of Patent:
November 5, 2019
Assignee:
Nektar Therapeutics
Inventors:
Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.
Type:
Grant
Filed:
October 3, 2017
Date of Patent:
November 5, 2019
Assignee:
Nektar Therapeutics
Inventors:
Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
Abstract: The invention provides for preparing a polymer-active agent conjugate, the method comprising the steps of reacting an amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.
Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
Type:
Grant
Filed:
February 28, 2018
Date of Patent:
October 8, 2019
Assignee:
Nektar Therapeutics
Inventors:
Lin Cheng, Jennifer Riggs-Sauthier, Neel K. Anand
Abstract: Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions.
Type:
Grant
Filed:
June 23, 2017
Date of Patent:
September 24, 2019
Assignee:
Nektar Therapeutics
Inventors:
Antoni Kozlowski, Jon McKannan, Samuel P. McManus
Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, and R6 are as described herein. The compounds of Formula I are agonists of the kappa opioid receptor and relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology, organic chemistry and polymer chemistry.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
September 10, 2019
Assignee:
Nektar Therapeutics
Inventors:
Neel K. Anand, Franco J. Duarte, Wen Zhang, Zhongxu Ren
Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
Abstract: Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.
Type:
Grant
Filed:
December 18, 2015
Date of Patent:
June 18, 2019
Assignee:
Nektar Therapeutics
Inventors:
Franco J. Duarte, Neel K. Anand, Wen Zhang, Pankaj Sharma, Devendrapratap Singh
Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
Type:
Grant
Filed:
August 25, 2016
Date of Patent:
June 4, 2019
Assignee:
Nektar Therapeutics
Inventors:
Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
Type:
Grant
Filed:
March 2, 2017
Date of Patent:
April 9, 2019
Assignee:
Nektar Therapeutics
Inventors:
Andreas Kordikowski, Stephen Ernest Walker, Peter York
Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
Type:
Grant
Filed:
August 29, 2017
Date of Patent:
April 9, 2019
Assignee:
Nektar Therapeutics
Inventors:
Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
Abstract: Conjugates of an anti-TNF antibody and one or more nonpeptidic water-soluble polymers are provided. Typically, the nonpeptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.
Type:
Grant
Filed:
March 27, 2017
Date of Patent:
March 19, 2019
Assignee:
Nektar Therapeutics
Inventors:
Mary J. Bossard, Gayle Stephenson-Phillips